IS6727A - Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar - Google Patents
Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlarInfo
- Publication number
- IS6727A IS6727A IS6727A IS6727A IS6727A IS 6727 A IS6727 A IS 6727A IS 6727 A IS6727 A IS 6727A IS 6727 A IS6727 A IS 6727A IS 6727 A IS6727 A IS 6727A
- Authority
- IS
- Iceland
- Prior art keywords
- glucogenophosphorylase
- pyrrolylamide
- inhibitors
- ring
- amide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0021831.3A GB0021831D0 (en) | 2000-09-06 | 2000-09-06 | Chemical compounds |
PCT/SE2001/001880 WO2002020530A1 (en) | 2000-09-06 | 2001-08-31 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
IS6727A true IS6727A (is) | 2003-02-24 |
IS2110B IS2110B (is) | 2006-05-15 |
Family
ID=9898927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6727A IS2110B (is) | 2000-09-06 | 2003-02-24 | Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar |
Country Status (31)
Country | Link |
---|---|
US (1) | US20030232875A1 (is) |
EP (1) | EP1317459B1 (is) |
JP (1) | JP2004508376A (is) |
KR (1) | KR100802369B1 (is) |
CN (2) | CN1264846C (is) |
AT (1) | ATE263772T1 (is) |
AU (2) | AU8283301A (is) |
BG (1) | BG107624A (is) |
BR (1) | BR0113606A (is) |
CA (1) | CA2417594A1 (is) |
CZ (1) | CZ2003616A3 (is) |
DE (1) | DE60102710T2 (is) |
DK (1) | DK1317459T3 (is) |
EE (1) | EE200300083A (is) |
ES (1) | ES2217183T3 (is) |
GB (1) | GB0021831D0 (is) |
HK (1) | HK1055299A1 (is) |
HU (1) | HUP0400784A3 (is) |
IL (1) | IL154291A0 (is) |
IS (1) | IS2110B (is) |
MX (1) | MXPA03001512A (is) |
NO (1) | NO20031024L (is) |
NZ (1) | NZ524011A (is) |
PL (1) | PL361024A1 (is) |
PT (1) | PT1317459E (is) |
RU (1) | RU2003104013A (is) |
SK (1) | SK2592003A3 (is) |
TR (1) | TR200401659T4 (is) |
UA (1) | UA73781C2 (is) |
WO (1) | WO2002020530A1 (is) |
ZA (1) | ZA200301013B (is) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
PE20020856A1 (es) * | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
GB0205166D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
DE10215908B4 (de) * | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
DE10215907A1 (de) * | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
DE10225635C1 (de) * | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
DK1375477T3 (da) * | 2002-06-17 | 2010-01-25 | Saltigo Gmbh | Fremgangsmåde til fremstilling af mono-N-sulfonylerede diaminer |
WO2004007437A1 (de) * | 2002-07-11 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
EP1388535A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
EP1562899A2 (en) * | 2002-11-07 | 2005-08-17 | Pfizer Products Inc. | N-(indole-2-carbonyl)amides as anti-diabetic agents |
BRPI0409465A (pt) * | 2003-04-17 | 2006-05-02 | Pfizer Prod Inc | derivados de carboxamida como agentes antidiabéticos |
US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
CA2525502C (en) * | 2003-05-21 | 2012-12-18 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
WO2004113345A1 (ja) * | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
GB0318464D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0318463D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0319759D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
GB0319690D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
WO2005020986A1 (en) * | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity |
WO2005020985A1 (en) * | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity |
GB0320422D0 (en) * | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
NZ548212A (en) | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
WO2006055462A1 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
WO2006055435A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
DE602005008099D1 (de) * | 2004-12-02 | 2008-08-21 | Prosidion Ltd | Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase |
WO2006059163A1 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Treatment of diabetes with glycogen phosphorylase inhibitors |
JP2008526999A (ja) | 2005-01-19 | 2008-07-24 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン |
KR20070107108A (ko) * | 2005-02-05 | 2007-11-06 | 아스트라제네카 아베 | 화학적 화합물 |
EP1848693A1 (en) * | 2005-02-05 | 2007-10-31 | AstraZeneca AB | Indan-amide derivatives with glycogen phosphorylase inhibitory activity |
KR101381768B1 (ko) | 2006-01-06 | 2014-04-07 | 선오비온 파마슈티컬스 인코포레이티드 | 테트랄론-기재 모노아민 재흡수 저해제 |
JP5432526B2 (ja) | 2006-01-06 | 2014-03-05 | サノビオン ファーマシューティカルズ インク | モノアミン再取り込み阻害剤としてのシクロアルキルアミン |
AU2007233041B2 (en) | 2006-03-31 | 2013-05-02 | Sepracor Inc. | Preparation of chiral amides and amines |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
NZ580429A (en) | 2007-05-31 | 2012-04-27 | Sepracor Inc | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US20100152200A1 (en) * | 2008-11-17 | 2010-06-17 | The Regents Of The University Of Michigan | Alphavirus inhibitors and uses thereof |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
CA2988601C (en) * | 2015-07-02 | 2021-12-07 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
US9815850B2 (en) * | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
KR20210111248A (ko) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제 |
US20230127046A1 (en) * | 2019-11-27 | 2023-04-27 | Riken | G9a INHIBITOR |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3706810A (en) * | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
US4692522A (en) * | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
US4599198A (en) * | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
US4720503A (en) * | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
US4668769A (en) * | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
FR2601368B1 (fr) * | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
DE3629545A1 (de) * | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
US4751231A (en) * | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
ES2081747B1 (es) * | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
US5863903A (en) * | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
FR2723739B1 (fr) * | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
US6107329A (en) * | 1995-06-06 | 2000-08-22 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
US5952322A (en) * | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
JP2002506073A (ja) * | 1998-03-12 | 2002-02-26 | ノボ ノルディスク アクティーゼルスカブ | プロテイン・チロシン・ホスファターゼ(PTPases)のモジュレーター |
DK1088824T3 (da) * | 1999-09-30 | 2004-04-13 | Pfizer Prod Inc | Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer |
CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
-
2000
- 2000-09-06 GB GBGB0021831.3A patent/GB0021831D0/en not_active Ceased
-
2001
- 2001-08-31 HU HU0400784A patent/HUP0400784A3/hu unknown
- 2001-08-31 NZ NZ524011A patent/NZ524011A/en unknown
- 2001-08-31 DK DK01961577T patent/DK1317459T3/da active
- 2001-08-31 BR BR0113606-2A patent/BR0113606A/pt not_active IP Right Cessation
- 2001-08-31 PT PT01961577T patent/PT1317459E/pt unknown
- 2001-08-31 EP EP01961577A patent/EP1317459B1/en not_active Expired - Lifetime
- 2001-08-31 ES ES01961577T patent/ES2217183T3/es not_active Expired - Lifetime
- 2001-08-31 KR KR1020037003265A patent/KR100802369B1/ko not_active IP Right Cessation
- 2001-08-31 TR TR2004/01659T patent/TR200401659T4/xx unknown
- 2001-08-31 AU AU8283301A patent/AU8283301A/xx active Pending
- 2001-08-31 UA UA2003021026A patent/UA73781C2/uk unknown
- 2001-08-31 CZ CZ2003616A patent/CZ2003616A3/cs unknown
- 2001-08-31 AT AT01961577T patent/ATE263772T1/de not_active IP Right Cessation
- 2001-08-31 CN CNB018183220A patent/CN1264846C/zh not_active Expired - Fee Related
- 2001-08-31 MX MXPA03001512A patent/MXPA03001512A/es active IP Right Grant
- 2001-08-31 PL PL01361024A patent/PL361024A1/xx unknown
- 2001-08-31 CN CNA2006100818966A patent/CN1896078A/zh active Pending
- 2001-08-31 US US10/344,506 patent/US20030232875A1/en not_active Abandoned
- 2001-08-31 WO PCT/SE2001/001880 patent/WO2002020530A1/en active IP Right Grant
- 2001-08-31 CA CA002417594A patent/CA2417594A1/en not_active Abandoned
- 2001-08-31 AU AU2001282833A patent/AU2001282833B2/en not_active Ceased
- 2001-08-31 IL IL15429101A patent/IL154291A0/xx unknown
- 2001-08-31 RU RU2003104013/04A patent/RU2003104013A/ru not_active Application Discontinuation
- 2001-08-31 SK SK259-2003A patent/SK2592003A3/sk unknown
- 2001-08-31 JP JP2002525151A patent/JP2004508376A/ja not_active Withdrawn
- 2001-08-31 DE DE60102710T patent/DE60102710T2/de not_active Expired - Fee Related
- 2001-08-31 EE EEP200300083A patent/EE200300083A/xx unknown
-
2003
- 2003-02-05 ZA ZA200301013A patent/ZA200301013B/en unknown
- 2003-02-24 IS IS6727A patent/IS2110B/is unknown
- 2003-03-05 NO NO20031024A patent/NO20031024L/no not_active Application Discontinuation
- 2003-03-10 BG BG107624A patent/BG107624A/bg unknown
- 2003-10-16 HK HK03107519A patent/HK1055299A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS6727A (is) | Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar | |
MY127126A (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | |
YU20999A (sh) | Heterociklični derivati koji inhibiraju faktor xa | |
IL171977A (en) | Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same | |
WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
WO2001066564A3 (en) | Gamma-secretase inhibitors | |
JO2282B1 (en) | Oxazole derivatives | |
CA2336909A1 (en) | Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity | |
GEP20084357B (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
GB0225475D0 (en) | Therapeutic agents | |
CA2338220A1 (en) | Substituted imidazoles having cytokine inhibitory activity | |
BR0214277A (pt) | Solvatos de paclitaxel | |
NO20052182L (no) | Nye forbindelser | |
CA2260777A1 (en) | Pentafluorobenzenesulfonamides and analogs | |
CA2303498A1 (en) | Dioxocyclopentyl hydroxamic acids | |
DE60045508D1 (de) | Dalda-analoge und ihre verwendung | |
IL149586A0 (en) | Pyrimidine derivatives as selective inhibitors of cox-2 | |
PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
GB9502644D0 (en) | Heterocyclic derivatives | |
AP2000001761A0 (en) | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase. | |
NO20060803L (no) | Orodispersibel farmasoytisk sammensetning av en antitrombotisk forbindelse | |
PT1056754E (pt) | Derivados fosfatados de 1,3,4-oxadiazolona de diarilo | |
AP2000001760A0 (en) | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase. | |
WO2004037166A3 (en) | Therapeutic guanidines | |
WO2001005386A3 (en) | Pharmaceutical composition useful for the treatment of tinnitus and hearing loss |